ABT — Abbott Laboratories stock price and chart

ABT

Abbott LaboratoriesStock · HealthcareS&P 500 0.2% · Russell 1000 0.2% · US Stock Market 0.2% · Russell 3000 0.2% · MSCI World 0.2% · MSCI ACWI 0.2% · S&P 500 Equal Weight 0.2%

$101.95-1.36%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

40.050.060.070.080.090.0100.0110.0120.0130.0140.0050.0M100.0M$101.95

2026-09-11

Price$101.95

MA20$97.49

MA50$113.55

Vol46.4M

What would $1,000 invested in ABT be worth today? →

ABT returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $101.95
Change YTD: -17.12%
Next earnings: Oct 21, 2026
Market cap: 176.4B2016-09 62.3B2026-09 176.4B+183.3% over the window
Enterprise value: 205.3B
Shares outstanding: 1.7B2016-06 1.5B2026-06 1.7B+17.7% over the window
52W low: $81.97
52W high: $137.49
From 52W high: -25.85%
From 52W low: +24.37%
52W range: 36%
Beta: 0.58

Volume

Rel volume: 1.07×
30D volume: 7.8M
30D $ vol: 856.5M

Fundamentals

Sales (ttm): 46.6B2016-06 20.6B2026-06 46.6B+126.6% over the window
Sales/share: $26.922016-06 $13.982026-06 $26.92+92.5% over the window
EPS (ttm): $3.112016-06 $1.512026-06 $3.11+105.8% over the window
FCF (ttm): 7.8B2016-06 1.7B2026-06 7.8B+363.0% over the window
FCF/share: $4.522016-06 $1.152026-06 $4.52+293.3% over the window
Book value/share: $29.542016-06 $14.062026-06 $29.54+110.0% over the window
Net margin: 11.65%2016-06 11.1%2026-06 11.6%+5.1% over the window
ROE: 10.61%2016-06 11.0%2026-06 10.6%-3.7% over the window
ROA: 4.97%2016-06 5.7%2026-06 5.0%-13.1% over the window
Debt / equity: 0.58×2016-06 0.292026-06 0.58+99.1% over the window
Current ratio: 1.382016-06 1.502026-06 1.38-8.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: +8.07%2025-06-30 → 2026-06-3043.1B → 46.6B (+8.1% total)+5.01%2023-06-30 → 2026-06-3040.2B → 46.6B (+15.8% total)+2.98%2021-06-30 → 2026-06-3040.2B → 46.6B (+15.8% total)+8.53%2016-06-30 → 2026-06-3020.6B → 46.6B (+126.6% total)
Net income: -61.22%2025-06-30 → 2026-06-3014B → 5.4B (-61.2% total)+1.68%2023-06-30 → 2026-06-305.2B → 5.4B (+5.1% total)-3.18%2021-06-30 → 2026-06-306.4B → 5.4B (-14.9% total)+9.07%2016-06-30 → 2026-06-302.3B → 5.4B (+138.1% total)
FCF: +15.49%2025-06-30 → 2026-06-306.8B → 7.8B (+15.5% total)+12.55%2023-06-30 → 2026-06-305.5B → 7.8B (+42.6% total)-1.97%2021-06-30 → 2026-06-308.6B → 7.8B (-9.5% total)+16.56%2016-06-30 → 2026-06-301.7B → 7.8B (+363.0% total)
Shares: -0.58%2025-06-30 → 2026-06-301.7B → 1.7B (-0.6% total)-0.10%2023-06-30 → 2026-06-301.7B → 1.7B (-0.3% total)-0.48%2021-06-30 → 2026-06-301.8B → 1.7B (-2.4% total)+1.64%2016-06-30 → 2026-06-301.5B → 1.7B (+17.7% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -61.19%2025-06-30 → 2026-06-30$8.00 → $3.11 (-61.2% total)+1.84%2023-06-30 → 2026-06-30$2.94 → $3.11 (+5.6% total)-2.69%2021-06-30 → 2026-06-30$3.56 → $3.11 (-12.7% total)+7.48%2016-06-30 → 2026-06-30$1.51 → $3.11 (+105.8% total)
Sales/share: +8.70%2025-06-30 → 2026-06-30$24.77 → $26.92 (+8.7% total)+5.11%2023-06-30 → 2026-06-30$23.18 → $26.92 (+16.1% total)+3.48%2021-06-30 → 2026-06-30$22.69 → $26.92 (+18.6% total)+6.77%2016-06-30 → 2026-06-30$13.98 → $26.92 (+92.5% total)
FCF/share: +16.17%2025-06-30 → 2026-06-30$3.89 → $4.52 (+16.2% total)+12.65%2023-06-30 → 2026-06-30$3.16 → $4.52 (+43.0% total)-1.50%2021-06-30 → 2026-06-30$4.88 → $4.52 (-7.3% total)+14.68%2016-06-30 → 2026-06-30$1.15 → $4.52 (+293.3% total)
Book value/share: +1.67%2025-06-30 → 2026-06-30$29.05 → $29.54 (+1.7% total)+11.30%2023-06-30 → 2026-06-30$21.42 → $29.54 (+37.9% total)+9.15%2021-06-30 → 2026-06-30$19.07 → $29.54 (+54.9% total)+7.70%2016-06-30 → 2026-06-30$14.06 → $29.54 (+110.0% total)
Dividend/share: +6.90%2025-06-30 → 2026-06-30$2.32 → $2.48 (+6.9% total)+7.87%2023-06-30 → 2026-06-30$1.98 → $2.48 (+25.5% total)+8.81%2021-06-30 → 2026-06-30$1.63 → $2.48 (+52.5% total)+9.38%2016-06-30 → 2026-06-30$1.01 → $2.48 (+145.0% total)
Price: -23.16%2025-09-11 → 2026-09-11$132.65 → $101.95 (-23.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-0.16%2023-09-11 → 2026-09-11$102.45 → $101.95 (-0.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-4.57%2021-09-10 → 2026-09-11$128.80 → $101.95 (-20.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+9.53%2016-09-09 → 2026-09-11$41.01 → $101.95 (+148.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -21.38%2025-09-11 → 2026-09-11$129.65 → $101.95 (-21.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+1.94%2023-09-11 → 2026-09-11$96.25 → $101.95 (+5.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-2.69%2021-09-10 → 2026-09-11$116.86 → $101.95 (-12.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+11.61%2016-09-09 → 2026-09-11$33.97 → $101.95 (+200.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 32.8×2016-09 45.482026-09 32.52-28.5% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 24.0×2016-09 20.402026-09 24.01+17.7% over the window
Fwd P/E: 17.4×
P/S (ttm)Market cap ÷ TTM revenue.: 3.8×2016-09 3.012026-09 3.79+25.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.5×2016-09 3.002026-09 3.45+15.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 22.5×2016-09 34.382026-09 22.55-34.4% over the window
EV/EBITDA (fy): 19.0×
EV/Sales (ttm): 4.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.44%2016-06 2.7%2026-06 4.9%+81.1% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 2.43%
Dividend/share (fwd): $2.48
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 1.73B ÷ 1.74B. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 0.58%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (0.58%) + dividends paid over that year ($4.3B) ÷ market_cap_at(2025-06-30) ($236.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 2.38%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.8B) ÷ today's market cap ($176.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.04%2016-06 2.3%2026-06 1.2%-49.2% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.8B + TTM dividends $4.3B) ÷ today's market cap ($176.4B). Same caveat as the cash buyback yield.: 3.45%2016-06 4.7%2026-06 3.8%-17.8% over the window

Vs own 10Y history

P/E: 35th
P/OI: 19th
P/S: 16th
P/B: 18th
P/FCF: 11th

Bar = where today’s multiple sits in ABT’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-1.36%

-6.29%

-8.08%

+14.53%

YTD

-17.12%

-19.37%

-12.55%

Financial statements

Open full ABT financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Abbott Laboratories (ABT) trades at $101.95 with a live price and an interactive chart covering 43+ years of daily price history, plus key valuation metrics. ChartRow also publishes ABT’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full ABT financial statements →

ABT — Abbott Laboratories price, chart and key statistics